Biphasic insulin lispro
Brand names: Humalog Mix25, Humalog Mix50
A premixed (biphasic) insulin combining rapid-acting insulin lispro with an intermediate-acting protaminated component, given by subcutaneous injection for diabetes mellitus. This page covers the premixed formulation and its mealtime-related risks.
The product information gives no fixed dose: it is individual and set by the prescriber, or by your local protocol. See the product SmPC.
Clinical monograph
How it works
The rapid-acting lispro fraction controls post-meal glucose while the protaminated fraction provides a longer background effect; both lower blood glucose by enhancing cellular glucose uptake and reducing hepatic glucose production.
Prescribing in practice
- Hypoglycaemia is the principal hazard — the rapid component acts promptly, so the dose must be matched to meals and given in close relation to eating.
- Resuspend the cloudy suspension gently before each dose and never give it intravenously.
- Insulin requirements vary with illness, exercise, weight and renal function, and changes between insulin brands should be supervised.
Monitoring
Monitor capillary and longer-term blood glucose (HbA1c), injection sites and for hypoglycaemia, adjusting doses to meals and activity.
Counselling the patient
- Mix the pen until evenly cloudy and inject around mealtimes as directed.
- Know how to recognise and treat a hypo, and rotate injection sites.
- Never share pens or needles and review monitoring when unwell.
Evidence & guidelines
Premixed insulin lispro is supported by randomised trials showing effective control of post-prandial and overall glycaemia in diabetes.
Reference: NICE NG28; NICE NG17; JBDS; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016